<p>Cullen Frost Bankers Inc. 在最近向證券交易委員會提交的 13F 表格中表示，在第二季度將其在 GSK PLC Sponsored ADR (NYSE:GSK - 免費報告) 的持股增加了 4.7%。該公司在此期間購買了額外的 16,999 股後，持有該製藥公司 375,481 股股票。Cullen Frost Bankers Inc. 在 GSK 的持股在最近一個季度末價值為 14,418,000 美元。</p>
<ul>
<li>默克：購買此下跌的 4 個不容錯過的理由</li>
</ul>
<p>其他機構投資者最近也買賣了該公司的股票。Brighton Jones LLC 在第四季度收購了 GSK 的新股份，價值約為 528,000 美元。GAMMA Investing LLC 在第一季度將其在 GSK 的股份增加了 107.8%。GAMMA Investing LLC 目前持有 4,447 股該製藥公司的股票，價值 172,000 美元，此前在上個季度又收購了 2,307 股。Wealth Enhancement Advisory Services LLC 在第一季度將其在 GSK 的股份增加了 2.2%。Wealth Enhancement Advisory Services LLC 目前持有 178,510 股該製藥公司的股票，價值 6,915,000 美元，此前在上個季度又收購了 3,822 股。Oppenheimer Asset Management Inc. 在第一季度將其在 GSK 的股份增加了 20.0%。Oppenheimer Asset Management Inc. 目前持有 140,106 股該製藥公司的股票，價值 5,428,000 美元，此前在上個季度又收購了 23,369 股。最後，Aurora Private Wealth Inc. 在第一季度收購了 GSK 的新股份，價值約為 692,000 美元。15.74% 的股票由機構投資者和對沖基金持有。</p>
<h2>華爾街分析師預測增長</h2>
<p>多家券商最近對 GSK 發表了評論。Weiss Ratings 在 10 月 8 日的研究報告中重申了對 GSK 股票的 &#34;持有 (c)&#34; 評級。Wall Street Zen 在 9 月 5 日的研究報告中將 GSK 的評級從 &#34;買入&#34; 上調至 &#34;強力買入&#34;。七位股票研究分析師對該股票給予了持有評級，一位分析師對該公司發佈了賣出評級。根據 MarketBeat 的數據，GSK 目前的平均評級為 &#34;減持&#34;，平均目標價為 37.38 美元。</p>
<ul>
<li>在重置年後，Moderna 股票是否準備反彈？</li>
</ul>
<p><strong>查看我們關於 GSK 的最新報告</strong></p>
<h2>GSK 價格表現</h2>
<p>NYSE:GSK 週四開盤價為 44.21 美元。GSK PLC Sponsored ADR 的 52 周低點為 31.72 美元，52 周高點為 45.59 美元。該公司的速動比率為 0.57，流動比率為 0.87，債務與股本比率為 1.07。該公司的市值為 898.7 億美元，市盈率為 20.47，市盈增長比率為 1.98，貝塔值為 0.53。該股票的 50 日移動平均線為 41.31 美元，200 日移動平均線為 39.16 美元。</p>
<ul>
<li>分析師預測 Wave Life Sciences 在降息後有 85% 的上漲空間</li>
</ul>
<p>GSK (NYSE:GSK - 獲取免費報告) 最近在 7 月 30 日發佈了季度財報。該製藥公司報告每股收益為 1.23 美元，超出分析師一致預期的 1.12 美元，超出幅度為 0.11 美元。GSK 的股本回報率為 49.22%，淨利潤率為 10.81%。該公司在本季度的收入為 106.4 億美元，而分析師預期為 79.2 億美元。在去年同期，該公司每股收益為 0.43 美元。該公司的收入同比增長 1.3%。GSK 已將其 2025 財年的指引設定為每股收益 4.590-4.590。股票分析師預計 GSK PLC Sponsored ADR 本年度將發佈每股收益 4.14 美元。</p>
<h2>GSK 減少股息</h2>
<p>該公司最近還宣佈了季度股息，該股息於 10 月 9 日支付。8 月 15 日的登記投資者獲得了每股 0.4206 美元的股息。這代表着年化股息為 1.68 美元，收益率為 3.8%。該股息的除息日期為 8 月 15 日。GSK 目前的派息比率為 78.24%。</p>
<h2>GSK 概況</h2>
<p>(免費報告)</p>
<p>GSK plc 及其子公司從事疫苗的研究、開發和生產，以及用於預防和治療疾病的專科和普通藥物，業務遍及英國、美國及國際市場。它通過兩個部門運營，分別是商業運營和全面研發。</p>
<h2>精選文章</h2>
<ul>
<li>我們更看好的五隻股票比 GSK 更好</li>
<li>什麼是 MarketRank™？如何使用它</li>
<li>Archer 最近的一系列勝利標誌着新的增長階段</li>
<li>如何計算投資回報率 (ROI)</li>
<li>3 只關鍵股票在基本面改善中推動回購</li>
<li>納斯達克是什麼？完整概述及歷史</li>
<li>選擇股票的最佳 AI，按表現排名</li>
</ul>
<p><strong>想看看其他對沖基金持有 GSK 的情況嗎？</strong> 訪問 HoldingsChannel.com 獲取 GSK PLC Sponsored ADR (NYSE:GSK - 免費報告) 的最新 13F 文件和內部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUdTSw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUdTSw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 GSK 嗎？</h2>
<p>在考慮 GSK 之前，你需要聽聽這個。</p>
<p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每天推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場關注之前購買……而 GSK 並不在名單上。</p>
<p>雖然 GSK 目前在分析師中被評為減持，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

GSK.WI

葛蘭素史克

<p>Cullen Frost Bankers Inc. 在第二季度增加了對 GSK PLC Sponsored ADR 的持股，增幅為 4.7%，目前持有 375,481 股，價值 1440 萬美元。其他機構投資者也調整了他們的持股。GSK 的股票在過去 52 周的價格區間為 31.72 美元至 45.59 美元，目前價格為 44.21 美元。該公司報告第二季度每股收益為 1.23 美元，超出預期，營收為 106.4 億美元。GSK 最近宣佈每股季度股息為 0.4206 美元，收益率為 3.8%</p>

<p>Cullen Frost Bankers Inc. raised its holdings in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 4.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 375,481 shares of the pharmaceutical company's stock after purchasing an additional 16,999 shares during the period. Cullen Frost Bankers Inc.'s holdings in GSK were worth $14,418,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Cullen Frost Bankers Inc. 在最近向證券交易委員會提交的 13F 表格中表示，在第二季度將其在 GSK PLC Sponsored ADR (NYSE:GSK - 免費報告) 的持股增加了 4.7%。該公司在此期間購買了額外的 16,999 股後，持有該製藥公司 375,481 股股票。Cullen Frost Bankers Inc. 在 GSK 的持股在最近一個季度末價值為 14,418,000 美元。</p>
</div><ul>
<li>Merck: 4 No-Brainer Reasons to Buy This Dip</li>
</ul>
<div class="lb-trans"><ul>
<li>默克：購買此下跌的 4 個不容錯過的理由</li>
</ul>
</div><p>Other institutional investors also recently bought and sold shares of the company. Brighton Jones LLC acquired a new stake in shares of GSK in the fourth quarter worth approximately $528,000. GAMMA Investing LLC boosted its stake in shares of GSK by 107.8% in the first quarter. GAMMA Investing LLC now owns 4,447 shares of the pharmaceutical company's stock worth $172,000 after acquiring an additional 2,307 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its stake in shares of GSK by 2.2% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 178,510 shares of the pharmaceutical company's stock worth $6,915,000 after acquiring an additional 3,822 shares during the last quarter. Oppenheimer Asset Management Inc. boosted its stake in shares of GSK by 20.0% in the first quarter. Oppenheimer Asset Management Inc. now owns 140,106 shares of the pharmaceutical company's stock worth $5,428,000 after acquiring an additional 23,369 shares during the last quarter. Finally, Aurora Private Wealth Inc. acquired a new stake in shares of GSK in the first quarter worth approximately $692,000. 15.74% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他機構投資者最近也買賣了該公司的股票。Brighton Jones LLC 在第四季度收購了 GSK 的新股份，價值約為 528,000 美元。GAMMA Investing LLC 在第一季度將其在 GSK 的股份增加了 107.8%。GAMMA Investing LLC 目前持有 4,447 股該製藥公司的股票，價值 172,000 美元，此前在上個季度又收購了 2,307 股。Wealth Enhancement Advisory Services LLC 在第一季度將其在 GSK 的股份增加了 2.2%。Wealth Enhancement Advisory Services LLC 目前持有 178,510 股該製藥公司的股票，價值 6,915,000 美元，此前在上個季度又收購了 3,822 股。Oppenheimer Asset Management Inc. 在第一季度將其在 GSK 的股份增加了 20.0%。Oppenheimer Asset Management Inc. 目前持有 140,106 股該製藥公司的股票，價值 5,428,000 美元，此前在上個季度又收購了 23,369 股。最後，Aurora Private Wealth Inc. 在第一季度收購了 GSK 的新股份，價值約為 692,000 美元。15.74% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>A number of brokerages recently commented on GSK. Weiss Ratings reiterated a &#34;hold (c)&#34; rating on shares of GSK in a research report on Wednesday, October 8th. Wall Street Zen upgraded GSK from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report on Friday, September 5th. Seven equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, GSK presently has an average rating of &#34;Reduce&#34; and an average target price of $37.38.</p>
<div class="lb-trans"><p>多家券商最近對 GSK 發表了評論。Weiss Ratings 在 10 月 8 日的研究報告中重申了對 GSK 股票的 &#34;持有 (c)&#34; 評級。Wall Street Zen 在 9 月 5 日的研究報告中將 GSK 的評級從 &#34;買入&#34; 上調至 &#34;強力買入&#34;。七位股票研究分析師對該股票給予了持有評級，一位分析師對該公司發佈了賣出評級。根據 MarketBeat 的數據，GSK 目前的平均評級為 &#34;減持&#34;，平均目標價為 37.38 美元。</p>
</div><ul>
<li>After a Reset Year, Is Moderna Stock Poised for a Comeback?</li>
</ul>
<div class="lb-trans"><ul>
<li>在重置年後，Moderna 股票是否準備反彈？</li>
</ul>
</div><p><strong>View Our Latest Report on GSK</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 GSK 的最新報告</strong></p>
</div><h2>GSK Price Performance</h2>
<div class="lb-trans"><h2>GSK 價格表現</h2>
</div><p>NYSE:GSK opened at $44.21 on Thursday. GSK PLC Sponsored ADR has a 52 week low of $31.72 and a 52 week high of $45.59. The company has a quick ratio of 0.57, a current ratio of 0.87 and a debt-to-equity ratio of 1.07. The company has a market capitalization of $89.87 billion, a P/E ratio of 20.47, a P/E/G ratio of 1.98 and a beta of 0.53. The stock's fifty day moving average is $41.31 and its two-hundred day moving average is $39.16.</p>
<div class="lb-trans"><p>NYSE:GSK 週四開盤價為 44.21 美元。GSK PLC Sponsored ADR 的 52 周低點為 31.72 美元，52 周高點為 45.59 美元。該公司的速動比率為 0.57，流動比率為 0.87，債務與股本比率為 1.07。該公司的市值為 898.7 億美元，市盈率為 20.47，市盈增長比率為 1.98，貝塔值為 0.53。該股票的 50 日移動平均線為 41.31 美元，200 日移動平均線為 39.16 美元。</p>
</div><ul>
<li>Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut</li>
</ul>
<div class="lb-trans"><ul>
<li>分析師預測 Wave Life Sciences 在降息後有 85% 的上漲空間</li>
</ul>
</div><p>GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share for the quarter, beating analysts' consensus estimates of $1.12 by $0.11. GSK had a return on equity of 49.22% and a net margin of 10.81%.The business had revenue of $10.64 billion during the quarter, compared to analysts' expectations of $7.92 billion. During the same period in the previous year, the firm posted $0.43 earnings per share. The company's revenue was up 1.3% on a year-over-year basis. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. Equities analysts expect that GSK PLC Sponsored ADR will post 4.14 EPS for the current year.</p>
<div class="lb-trans"><p>GSK (NYSE:GSK - 獲取免費報告) 最近在 7 月 30 日發佈了季度財報。該製藥公司報告每股收益為 1.23 美元，超出分析師一致預期的 1.12 美元，超出幅度為 0.11 美元。GSK 的股本回報率為 49.22%，淨利潤率為 10.81%。該公司在本季度的收入為 106.4 億美元，而分析師預期為 79.2 億美元。在去年同期，該公司每股收益為 0.43 美元。該公司的收入同比增長 1.3%。GSK 已將其 2025 財年的指引設定為每股收益 4.590-4.590。股票分析師預計 GSK PLC Sponsored ADR 本年度將發佈每股收益 4.14 美元。</p>
</div><h2>GSK Cuts Dividend</h2>
<div class="lb-trans"><h2>GSK 減少股息</h2>
</div><p>The business also recently announced a quarterly dividend, which was paid on Thursday, October 9th. Investors of record on Friday, August 15th were paid a dividend of $0.4206 per share. This represents a $1.68 annualized dividend and a yield of 3.8%. The ex-dividend date of this dividend was Friday, August 15th. GSK's payout ratio is presently 78.24%.</p>
<div class="lb-trans"><p>該公司最近還宣佈了季度股息，該股息於 10 月 9 日支付。8 月 15 日的登記投資者獲得了每股 0.4206 美元的股息。這代表着年化股息為 1.68 美元，收益率為 3.8%。該股息的除息日期為 8 月 15 日。GSK 目前的派息比率為 78.24%。</p>
</div><h2>GSK Profile</h2>
<div class="lb-trans"><h2>GSK 概況</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免費報告)</p>
</div><p>GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&amp;D.</p>
<div class="lb-trans"><p>GSK plc 及其子公司從事疫苗的研究、開發和生產，以及用於預防和治療疾病的專科和普通藥物，業務遍及英國、美國及國際市場。它通過兩個部門運營，分別是商業運營和全面研發。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than GSK</li>
<li>What is MarketRank™? How to Use it</li>
<li>Archer’s Recent String of Victories Signals a New Phase of Growth</li>
<li>How to Calculate Return on Investment (ROI)</li>
<li>3 Key Stocks Boosting Buybacks Amid Improving Fundamentals</li>
<li>What is the Nasdaq? Complete Overview with History</li>
<li>The Best AI for Picking Stocks, Ranked by Performance</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 GSK 更好</li>
<li>什麼是 MarketRank™？如何使用它</li>
<li>Archer 最近的一系列勝利標誌着新的增長階段</li>
<li>如何計算投資回報率 (ROI)</li>
<li>3 只關鍵股票在基本面改善中推動回購</li>
<li>納斯達克是什麼？完整概述及歷史</li>
<li>選擇股票的最佳 AI，按表現排名</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding GSK?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK PLC Sponsored ADR (NYSE:GSK - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對沖基金持有 GSK 的情況嗎？</strong> 訪問 HoldingsChannel.com 獲取 GSK PLC Sponsored ADR (NYSE:GSK - 免費報告) 的最新 13F 文件和內部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUdTSw" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=GSK"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in GSK Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 GSK 嗎？</h2>
</div><p>Before you consider GSK, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 GSK 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師及其每天推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場關注之前購買……而 GSK 並不在名單上。</p>
</div><p>While GSK currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 GSK 目前在分析師中被評為減持，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Cullen Frost Bankers Inc. 購入了 GSK PLC Sponsored ADR $GSK 的股份